GlaxoSmithKline Review Supports Avandia, FDA To Review Data
9th Jul 2010 14:39
LONDON (Dow Jones)--GlaxoSmithKline PLC (GSK.LN), a global healthcare group, said Friday its review supports the overall positive benefit-risk profile of Avandia (rosiglitazone maleate) as an important medicine for patients with type 2 diabetes. MAIN FACTS: -The data in GSK's review come fro
Read moreBEFORE THE BELL: US Stock Futures Lower; Google Up On China News
9th Jul 2010 14:15
By Steve Goldstein U.S. stock futures gave back some of this week's strong gains Friday as traders position portfolios ahead of the release of second-quarter earnings and Google rose in premarket trade after the Internet search giant renewed its Chinese license. Futures on the Dow Jones Ind
Read moreBEFORE THE BELL: US Stock Futures Mixed; Google Up On China News
9th Jul 2010 12:45
By Steve Goldstein U.S. stock futures were in tight range Friday after a strong week, as traders position portfolios ahead of the release of second-quarter earnings. Google rose in premarket trade after the Internet search giant renewed its Chinese license. Futures on the Dow Jones Industri
Read moreLondon midday: Stocks becalmed
9th Jul 2010 11:59
After a bright start things in London have tailed off with those traders still chained to their screens probably contemplating an early getaway for the week-end. Constituents of the FTSE 100 index are almost exactly divided between leaders and laggards, with insurers and base metal miners prominent
Read moreEU Drug Panel Starts Review Of Rosiglitazone-Containing Medicines
9th Jul 2010 10:13
LONDON (Dow Jones)--The European Medicines Agency said Friday it has started a review of the rosiglitazone-containing anti-diabetes medicines Avandia, Avandamet and Avaglim, to determine whether new data on the risk of cardiovascular problems have an impact on their benefit-risk profile. MAIN FA
Read moreGlaxoSmithKline: EMEA To Review Profile Of Avandia (Rosiglitazone)
9th Jul 2010 10:09
LONDON (Dow Jones)--GlaxoSmithKline PLC (GSK.LN), a global healthcare group confirmed Friday that on behalf of the European Medicines Agency or EMEA, the Committee for Medicinal Products for Human Use or CHMP, is to review the benefit/risk profile of Avandia (rosiglitazone). MAIN FACTS: -Thi
Read moreLondon open: Footsie up again
9th Jul 2010 08:57
London has started brightly buoyed by another strong performance overnight on Wall Street and a rash of upbeat company announcements. Miners are leading the way following the big gains in the US. Antofagasta, ENRC and Rio Tinto are the best performers. On the downside, National Grid, GlaxoSmithKlin
Read moreJ&J Starts Disclosing Drug Unit's Payments To Doctors >JNJ
8th Jul 2010 20:49
By Peter Loftus Of DOW JONES NEWSWIRES Johnson & Johnson (JNJ) publicly disclosed payments to doctors for the first time, becoming the latest drug maker to try to improve transparency surrounding its marketing practices. But if investors want to browse the J&J data or look at the big pic
Read moreMARKET TALK: UBS Lifts Genmab Target Price
8th Jul 2010 09:41
0841 GMT [Dow Jones] UBS lifts Genmab (GEN.KO) target price to DKK60 from DKK44, after removing the 25% refinancing risk discount introduced earlier. Says Genmab appears to have no intention of restructuring further despite GlaxoSmithKline (GSK) taking on more of the Arzerra drug development work an
Read moreUS HOT STOCKS: PolyOne, Sirius, VeriSign, XenoPort -3-
7th Jul 2010 22:08
Sidoti & Co. raised its stock-investment rating on PolyOne Corp. (POL, $8.41, +$0.97, +13.04%), a producer and distributor of resin and other plastic additives, to buy from neutral, saying investors are ignoring the earnings recovery the firm contends is underway. Sirius XM Radio Inc. (SIRI, $1
Read moreUS HOT STOCKS: Dollar Thrifty, Netlist, PolyOne, XenoPort -2-
7th Jul 2010 18:20
China-Biotics Inc. (CHBT, $12.82, +$0.86, +7.19%), a developer, manufacturer and distributor of probiotics products in China, has approved a new share-repurchase program of up to $20 million of its common shares over the next 12 months. Cree Inc. (CREE, $63.96, +$3.00, +4.92%) and Philips Elect
Read moreXenoPort, Glaxo Migrane Drug Fails To Outperform Placebo
7th Jul 2010 14:05
DOW JONES NEWSWIRES GlaxoSmithKline PLC (GSK, GSK.LN) and XenoPort Inc. (XNPT) said a drug didn't produce statistically significant improvement in treating migraine headaches than a placebo in a midstage trial. The 30-week study included 526 patients at four dosing levels twice a day, and t
Read moreGlaxoSmithKline: No Improvement For GSK1838262/XP13512 Vs Placebo
7th Jul 2010 13:45
LONDON (Dow Jones)--Pharmaceutical firms GlaxoSmithKline PLC (GSK) and XenoPort, Inc. (XNPT) said Wednesday GSK1838262/XP13512 (gabapentin enacarbil) didn't demonstrate a statistically significant improvement compared to placebo as a prophylactic treatment for migraine headaches. MAIN FACTS:
Read morePRESS RELEASE: GlaxoSmithKline and XenoPort Report Top-Line Phase 2b Results for GSK1838262/XP13512 as a Prophylactic Treatment for Migraine Headache
7th Jul 2010 13:30
RESEARCH TRIANGLE PARK, N.C. & SANTA CLARA, Calif.--(BUSINESS WIRE)--July 07, 2010-- GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (Nasdaq:XNPT) announced today that GSK1838262/XP13512 (gabapentin enacarbil) did not demonstrate a statistically significant improvement compared to placebo as a pro
Read moreOn Dow Jones Investment Banker Today: Genmab, Standard Chartered
6th Jul 2010 17:36
LONDON (Dow Jones Investment Banker)--The following columns have been published exclusively on Dow Jones Investment Banker in recent days. Many Dow Jones Investment Banker columns contain spreadsheets, video, PDFs and other supporting material. To arrange access to the best of Dow Jones news and opi
Read more